May 1, 2026 · Form 4 insider transaction
Baynes Roy D. sold 9,750 shares of Travere Therapeutics, Inc. at $44.22 per share, a transaction worth $431.1K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 3 days after the transaction.
This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person.